The mTOR inhibitor compound RTP had comparable anti-tumor activity to sorafenib in HCC organs, and it was also found that targeting the mTOR pathway could effectively treat acquired sorafenib-resistant HCC organs [65]. Here, MTOR is linked to neoplasm.